ClinicalTrials.gg

Program

spinosad

Also written as “Spinosad”, “APT-001 topical ophthalmic ointment (spinosad)” and “DE-105 ophthalmic solution”.

Its studies are mostly in Blepharitis · Lice Infestations · Epilepsy, led by 4 companies.

Furthest: phase 4, since Aug 6, 20128 company-led studies, 1 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ParaPRO40 open or runningphase 4since Aug 6, 2012Oct 15, 2007none ahead
Aperta Biosciences21 open or runningphase 2since Dec 3, 2024Dec 3, 2024Jan 2027phase 2 · NCT07904767
Santen Pharmaceutical10 open or runningphase 2since Sep 30, 2009Sep 30, 2009none ahead
Takeda10 open or runningphase 1since Jul 9, 2015Jul 9, 2015none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 15, 2007First studies: 2 phase 3 studiesNew to ParaPROParaPRO · NCT00545753, NCT00545168
  2. Dec 28, 2007Phase 1 study in Head LiceParaPRO · NCT00591331 · 37 enrolled · United States
  3. Sep 30, 2009Santen Pharmaceutical's first study: phase 2 study in Persistent Corneal Epithelial DefectNew to Santen PharmaceuticalSanten Pharmaceutical · NCT00988494 · 45 enrolled · Japan
  4. Aug 6, 2012Phase 4 study in Lice InfestationsParaPRO · NCT01660321 · 26 enrolled · United States
  5. Jul 9, 2015Takeda's first study: phase 1 study in EpilepsyNew to TakedaTakeda · NCT02497235 · 11 enrolled · United States
  6. Dec 3, 2024Aperta Biosciences's first study: phase 2 study in BlepharitisNew to Aperta BiosciencesAperta Biosciences · NCT06720896 · 66 enrolled · Guatemala
  7. Oct 23, 2026Phase 2 study in BlepharitisAperta Biosciences · NCT07904767 · 15 planned · Guatemala

Ahead

  1. Jan 2027Primary completion: phase 2 study in BlepharitisAperta Biosciences · NCT07904767

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Nicotinic acetylcholine receptor agonist”ChEMBL 37, by rule

Studies

All 8 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07904767Blepharitis · Guatemala2Not yet recruitingAperta BiosciencesJan 202715
NCT06720896Blepharitis · Guatemala2CompletedAperta BiosciencesJul 13, 202666
NCT02497235Epilepsy · United States1CompletedTakedaDec 201511
NCT01660321Lice Infestations · United States4CompletedParaPROOct 201126
NCT00988494Persistent Corneal Epithelial Defect · Japan2CompletedSanten Pharmaceutical45
NCT00591331Head Lice · United States1CompletedParaPRODec 200737
NCT00545753Lice Infestations · United States3CompletedParaPROMar 2008558
NCT00545168Pediculus Capitis Infestation · United States3CompletedParaPROMar 2008480

How it is read

Names in the registry

  • “Spinosad”, 4 entries
  • “APT-001 topical ophthalmic ointment (spinosad)”, 2 entries
  • “DE-105 ophthalmic solution”, 2 entries
  • “[18F]MNI-792 (tracer)”, 1 entry
  • “spinosad”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.